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Stem cell research and therapy are progressing these days dramatically. Stem cell therapy holds enormous treatment 
potential for many diseases which currently have no or limited therapeutic options. Unfortunately, this potential also 
comes with side-effects. In this review, the positive and negative effects of regulation of stem cells will be explained. Stem 
cells are undifferentiated cells which able to develop into many different cells of types in the body during early life and 
growth. There are five types of stem cells: embryonic stem cells, induced pluripotent stem cells, somatic stem cells, fetal 
stem cells and mesenchymal stem cells. Stem cell transplantation is one form of stem cell therapy, it comes with different 
techniques sourced, and those are autologous and allogeneic transplantation stem cells. In an autologous transplant, a 
patient's blood-forming stem cells are collected, meanwhile, in an allogeneic transplant, target cells are replaced with new 
stem cells obtained from a donor or donated umbilical cord blood. Its abilities to maintain the phenotype, self-renewing 
and differentiate itself into specialized cells, give rise to stem cell as an innovation for the treatment of various diseases. 
In the clinical setting, stem cells are being explored for different conditions, such as in tissue repair and regeneration and 
autoimmune diseases therapy. But along with its benefit, stem cell therapy also holds some harm. It is known that the 
treatment using stem cell for curing and rehabilitation has the risk of tumor formation.
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Introduction
A cell is the smallest unit of living matter and the basic 
functional unit of life. The human body is consists of 100 
trillion cells, and each cell is assigned to a specialized 
function to perform. Some cells function as the brain 
(neurons), while others as our hearts (cardiac myocytes), 
our skin (fibroblasts) our pancreas (pancreatic cells), etc. All 
these functional cells are originated from an unspecialized 
cell, called stem cell. Stem cells have two unique properties: 
they can multiply and become other types of cells 
(differentiated). 
 Stem cells have the potential to yield new therapies, 
new insights into disease and a clearer understanding of 
tissue formation and maintenance.1 Stem cell research and 
therapy have now progressed dramatically with countless 
research studies are being published each year in scientific 
journals. Stem cell therapy offers the promise to treat 
degenerative diseases, cancer, damaged tissues repairing and 
an alternate source of biological material for cell restorative 
treatments which currently have no or limited therapeutic 
options.2,3 There is no doubt that stem cell therapy holds 
huge potential. Unfortunately, this potential also comes with 
C e l l  a n d 
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side-effects. In this review, the positive and negative effects 
of regulation of stem cells will be explained.
Stem cells
Stem cells are undifferentiated cells that have the remarkable 
potential to develop into many different cell types of the 
body of early life and growth. The term “stem cell” goes 
far to 1908 when Russian histologist Alexander Maximow 
developed and introduced a theory of hematopoiesis, a 
theory upon which our present concept of blood cells' origin 
and differentiation is based. After being identified the first 
time for the hematopoietic system, they are also likely to 
be present in many other tissues. The field of stem cell is 
rapidly developing, it has changed the care of individuals 
with hematologic, oncologic, dermatologic, ophthalmologic 
and orthopedic conditions.2-4 The thriving role of stem cells 
in clinical medicine is developing along at least three lines: 
stem cells as therapy (either to replace cell lines that have 
been lost or destroyed or to modify the behavior of other 
cells), stem cells as targets of drug therapy and stem cells 
to generate differentiated tissue for in vitro study of disease 
models for drug development.5
 Stem cells are distinguished from other cell types by 
two important characteristics. First, they are unspecialized 
cells capable of renewing themselves through cell division, 
sometimes after long periods of inactivity. Stem cells are 
hypothesized to be able to divide symmetrically (in which 
both daughter cells are either stem cells or differentiated 
cells) or asymmetrically (yielding one stem cell and one more 
differentiated cell).5,6 Second, under certain physiologic or 
experimental conditions, they can be induced to become 
tissue- or organ-specific cells with special functions. In 
some organs, such as the gut and bone marrow, stem cells 
regularly divide to repair and replace worn out or damaged 
tissues. In other organs, however, such as the pancreas and 
the heart, stem cells only divide into special conditions.6,7
 Stem cells have potency to be either totipotent, 
pluripotent, multipotent or unipotent. Totipotent cells can 
form all types of cells in the body, including embryonic 
and extra-embryonic tissue. Pluripotent is able to make all 
cells of the embryo, including germ cells and cells from 
any of the germ layers. Meanwhile, multipotent cells can 
only make cells within a given germ layer. For instance, 
multipotent stem cells from a mesodermal tissue like the 
blood hematopoietic stem cell can make all the cells in the 
blood, but cannot produce cells of a different germ layer 
such as neural cells (ectoderm) or liver cells (endoderm). A 
unipotent stem cell has the capacity for make a single cell 
type. An example is a germ cell stem cell that makes the cells 
that mature to become egg or sperm, but not other cell types. 
The potency of cells is located at the time the embryonic 
development of organisms. Cells that have totipotency are 
arising from the first few cell divisions after fertilization of 
the egg. Pluripotent cells were thought to be limited to cells 
derived from either the inner cell mass of the blastocyst or 
nascent germ cells in the embryo. Now we have known that 
pluripotent cells can arise from other cell types as well. 
Within 10 to 14 days after conception of humans, most stem 
cells are restricted to be either multipotent or unipotent.6,7
Sources of stem cells
Embryonic stem cell (ESC)
The origin of the ESCs is the embryo. They came 7-10 
days after fertilization of the pre-implantation blastocyst. In 
the early 1960s, researchers isolated a single cell type of a 
teratocarcinoma, a tumor derived from a germ cell. These 
embryonal embryonic carcinoma cells are the stem cells of 
teratocarcinoma's which can be considered as the malignant 
counterparts of ESCs that originate from the inner cell mass 
of a blastocyst-stage embryo. The embryonal embryonic 
carcinoma cells replicate and grow in cell culture conditions.
 In 1981, ESCs were first derived from mouse 
embryos.8,9 The technique was by culturing the mouse 
ESCs from embryos in the uterus to increase cell numbers, 
allowing for the derivation of ESCs from these embryos. The 
development is continue to isolate and grow human ESCs 
in cell cultures in 1998.10 The research on teratocarcinoma, 
embryonal embryonic carcinoma cells and ESCs which 
have been carried out over the past 50 years passed through 
several distinct phases as seen in Figure 1.11
 ESCs are pluripotent cells that have the ability to 
differentiate between derivatives of all three germ layers 
(endoderm, mesoderm, and ectoderm). Pluripotent stem 
cells in mice have the potency to form chimeras after 
injection of early blastocysts. 11,12 ESCs are derived from 
totipotent cells of the inner cell mass of the blastocyst, an 
early stage mammalian embryo. These cells are capable of 
unlimited, undifferentiated proliferation in vitro. In mouse 
embryo chimeras ESCs can differentiate from a range of 
adult tissues. Also, human ESCs have a large differentiation 
potential and can form cells from all embryonic germ 
layers.10,13,14
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Figure 1. Timeline history of ESC research.11 (With permission from Nature Publishing Group).
Induced pluripotent stem cell (iPSC)
iPSCs are a type of pluripotent stem cells artificially 
derived from an adult differentiated somatic cell that is 
non-pluripotent. The transformation of an adult somatic cell 
into an iPSC was firstly achieved by inducing a "forced" 
expression of specific genes. At this moment, it has been 
demonstrated that the forced expression of a characterized 
set of transcription factors (Oct4, Sox2, c-Myc, Klf4, Nanog 
and Lin28) can reprogram human and mouse somatic cells 
into iPSCs.15-21 Most iPSC use fibroblasts for its generation, 
but iPSC can also been derived from liver, pancreas β-cells 
and mature B cells. ESC and iPSC are very similar despite 
the differences in their origins. They have very similar 
growth characteristics, gene expression profiles, epigenetic 
modifications and developmental potential.22-24 iPSCs are a 
revolutionary tool for generating in vitro models of human 
diseases and may help us to understand the molecular basis 
of epigenetic reprogramming.25
Somatic stem cell (SSC)
Multipotent adult stem cells or also known as SSC is found 
in differentiated tissues. The natural function of these 
cells is to maintenance and regenerate old or damaged 
tissue by replacing lost cells. SSC can be subdivided into 
different groups, depending on their morphology, cell 
surface markers, differentiation potential or tissue of origin. 
Scientific interest in somatic or adult stem cells has centered 
on their ability to divide or self-renew indefinitely, and (with 
certain limitations) differentiate to yield all the specialized 
cell types of the tissue from which it originated. In principle, 
SSC can be isolated from many tissues; however, cord 
blood and bone marrow are sources which are often used as 
a source of SSC for stem cell therapy. More lately, adipose 
tissue has also been used. Neural stem cells can be isolated 
from various regions of the adult brain and spinal cord.26,27
Fetal stem cell (FSC)
A relatively new stem cell type belongs to the group of 
FSC which can be derived either from the fetus or extra-
embryonic structures of fetal origin. FSCs do not form 
teratomas. Various subtypes of FSCs have been described 
based on the tissues from which they are derived (i.e., 
amniotic fluid, umbilical cord, Wharton's jelly, amniotic 
membrane and placenta). The relatively easy accessibility 
and high proliferation rate makes FSC ideal sources for 
regenerative medicine.28-31
Mesenchymal stem cell (MSC)
MSC which also referred to as mesenchymal or multipotent 
stromal cells was first discovered in the bone marrow in the 
early 1970s. First clinical trials performed with stem cells 
to repair the non-haematopoietic tissues do with MSC.32-
33 MSCs have been subsequently found in many tissues, 
such as umbilical cord blood, adipose, brain, liver and 
lungs.34-40 They seen as promising cells for the treatment 
of a large variety of disorders, including cardiovascular, 
neurodegenerative and autoimmune diseases.41-42 
Autologous and allogenic stem cells
Stem cell transplantation is a generic term covering 
different techniques. There are autologous and allogeneic 
transplantation stem cells. In an autologous transplant, 
patient's blood-forming stem cells are collected. Later, the 
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collected stem cells are transplanted back into the patient, 
allowing the bone marrow to produce the new cell. In 
an allogeneic transplant, a patient use stems cells from a 
donor. The new stem cells are then infused into patient's 
bloodstream through an intravenous catheter, in a procedure 
that is similar to a blood transfusion.43,44 Others route of 
administration such as intramuscular, intratracheal or 
intravitreous might be used for stem cell transplantation. 
 It is accepted that stem cell transplants for many 
diseases should be initiated using autologous grafts, which 
are less risky and less complicated than allogeneic grafts. 
Here, we review the current benefits and risks of using to 
stem cells as therapy, more specifically about the allogeneic 
stem cells.
Allogeneic therapy stem cell
The prior chapter describes the characteristics and sources of 
stem cells. Meanwhile, in this section, we will focus on the 
roles and benefits of stem cells, which are mainly related to 
the treatment of several diseases. Stem cell transplantation 
is currently used as a technique for the treatment of chronic 
diseases. Allogeneic therapy has been a focus on clinical 
application because it is more efficient regarding in product 
availability and the number of the cells.45
 Allogeneic therapy is clearly a disruptive concept 
of biological system, where the dogma of immunologic 
is that any foreign tissue will cause an immunological 
reaction. As the cell-based therapies develop, MSC is a 
prototype that has sufficient ability to evade or suppress 
the immune system, so far can be used as allografts without 
immunosuppression.45 MSCs were first described by 
Friedenstein as “colony forming units-fibroblastic” due to 
their ability to generate single cell-derived colonies, and 
are adult stem cell showed functional properties that have 
opened the way for cell-based clinical therapies.46,47 MSCs 
exhibit immunosuppressive as healing capacities to improve 
angiogenesis and prevent apoptosis or fibrosis through the 
secretion of paracrine mediators (Figure 2).47,48 
 The secretion of bioactive molecules consists 
of immunomodulation, anti-apoptosis, angiogenesis, 
support of the growth and differentiation of local 
stem and progenitor cells, anti-scarring and chemo-
attraction. The immunomodulatory effects of MSCs are 
Figure 2. Paracrine effect of MSCs.48(With permission from Springer Nature).
 21
Is Stem Cell a Curer or an Obstruction?Darmayanti S, et al.
Figure 3. MSCs exert immunomodulatory effects mainly through central and peripheral immune compartments.50 (With permission 
from Springer Nature).
inhibition of immune cell proliferation, the suppression 
of immunoglobulin production, the inhibition of dendritic 
cell maturation and the stimulation of regulatory T-cell 
proliferation. It also limits apoptosis and stimulates local 
angiogenesis through the secretion of extracellular matrix 
molecules.48
 The essential characteristics of MSCs are their 
immunomodulatory and anti-inflammatory effects (Figure 
3), and multipotent progenitor cells that have the capacity 
to differentiate into all lineages of mesodermal origin, e.g., 
cartilage, bone and adipocytes. Furthermore, MSCs can also 
be isolated from variety of tissues between multiple cell 
lineages, and possess unique immunomodulatory properties 
that ameliorate inflammation and immune responses.49,50,51
Application of allogeneic therapy stem cell
Allogeneic MSCs are subject to multiple quality controls 
compared to autologous therapy. Besides, the source of 
autologous use products derived from cells of the patient 
which are usually older and has multiple comorbidities. 
Cell products also depend on manufacture process and 
the expansion of the patient's cells are unpredictable. The 
process of autologous products require 4 to 6 weeks to 
reach sufficient numbers. In other hand, allogeneic products 
can be expanded on amount that may not be affordable for 
autologous source, undergo cryopreservation and will be 
available for delivery easier (Table 1).45,52 
 Allogeneic stem cell transplantation has the possibility 
of healing. It is because of the potential for immunologic 
graft-versus-host disease, lower rates of relapse for allograft 
over autograft recipients, and reduced levels and functional 
impairment of progenitor cells, whereas in autologous 
therapy relapses is a significant problem despite the fact that 
this treatment offer way safer side risks.53,54
 Allogeneic MSCs has multiple mechanisms including 
immune privileged and immunosuppression. MSCs are 
considered immune privileged because of their lack of 
expression of major compatibility complex class (MHC) 
II proteins and costimulatory molecules B7 and CD40 
ligand. They also exert immunosuppressive actions through 
inhibition of innate and adaptive immunity, e.g., inhibition 
of T cell proliferation of both T helper and cytotoxic T cells, 
decrease the production of the proinflammatory cytokines 
interferon -γ, tumor necrosis factor-α, and interleukin (IL)-
214, inhibit the activation of natural killer cells, arrest 
B-cell maturation and block maturation of dendritic cells. 
These are resulting in reduced expression of antigens and 
costimulatory molecules necessary to activate T cells and 
thus avoid rejection of transplantation.45,46,52,54
Clinical application of allogeneic therapy stem cell
Characteristics of stem cells are unique compared to other 
mammalian cells. First, they exist as unspecialized cells 
lacking tissue-specific features, and they maintain this 
phenotype until exposed to appropriate signals. Second, 
stem cells have the capacity for the self-renewal area. 
Third, under the local signal biology, it can differentiate 
into specialized cells with the phenotype completely 
different from that precursor. These gave rise to MSCs as 
a new and exciting innovation for the treatment of various 
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Autologous Cell Therapy Allogeneic Cell Therapy 
• Stem cells are from own body • Stem cells are from another human being 
• No immune response • Minimal immune response 
• Same environment as patient - process  
products require 4 to 6 weeks to reach 
sufficient numbers 
• Manufacturing failure dependent 
• Delayed delivery 
• Readily available 
• Guaranteed dosage 
• Products derived cells of patients are 
usually older and multiple comorbidities 
• Young health donors 
• Additional invasive procedure • No additional invasive procedure 
• High risk relapse • Low rate relapse 
 
Table 1. Comparison of autologous and allogeneic stem cell therapy.45,52,53,54
diseases associated with inflammation, tissue damage, and 
subsequent regeneration and repair.55,56 In the clinical setting, 
stem cell are being explored for trials of various conditions, 
including orthopedic injuries, graft onto host disease 
following bone marrow transplantation, cardiovascular 
diseases, autoimmune diseases, and liver diseases.57
Tissue repair and regeneration
Utilization of stem cell therapy for tissue repairs are done on 
cartilage and cell-based therapies for cartilage defects have 
evolved through a few generations with various cell sources, 
most developing MSCs which are a multipotent endogenous 
of progenitors capable of differentiation to musculoskeletal 
tissues.58,59 Cartilage defects in the weight-bearing joint are 
a strenuous limitation of the patient and pose a significant 
burden on society and need early treatment since they 
have a poor intrinsic healing capacity and tend to lead to 
osteoarthritis, where the characteristics of osteoarthritis are 
characterized by progressive and irreversible degeneration 
of cartilage.58,60,61 
 Application of MSCs throughout the body indicates 
the intrinsic role in tissue repairs and regeneration, with 
the ability of cells to form the mesoderm descent, able 
to differentiate towards osteoblasts, chondrocytes, and 
adipocytes.59 Intra-articular injection of MSCs in patients 
with osteoarthritis lead a strong improvement in the 
coverage and quality of cartilage, with the involvement of 
Transforming Growth Factor-Beta 1 (TGF-β1) and Insulin-
Like Growth Factor 1 (IGF-1) which has a synergistic action 
in stimulating chondrogenesis.60,62
Immune disorder therapy
The application of MSC as regenerative medicine is now 
developing as an immunotherapeutic agent which capable 
of multilineage differentiation and paracrine factors of the 
MSCs-derived were able to mediate the immunomodulatory 
function, especially against lymphocytes T.63
 The uses of MSCs in the treatment of autoimmune 
disease are used in multiple sclerosis, lupus, and 
inflammatory bowel diseases. Mechanism of MSCs in 
multiple sclerosis treatments is MSC suppress auto-
reactive Th1/Th17 proliferation and infiltration, as well as 
increasing accumulation of Th2 cytokines-IL-4 and IL-5-
and the generation of Tregs.63 The use of MSCs in reducing 
the lupus are capable of suppressing Th1 response.(64) In 
inflammatory bowel diseases, both Crohn's disease (CD) 
and ulcerative colitis (UC), MSC is a promising candidate 
for the treatment. MSC is able to decrease immune cells 
infiltration and TNF-α expression, but increases of TGF-β 
levels at sites of injury.63,65
Balance of stem cell through proliferation, 
differentiation and self-renewal
 The stem cell dynamic interaction with the microenvironment 
consequences of the fate of stem cell.66 It is used to ensure 
the balance of stem cells maintains in the one organism.67 
This reaction is controlled by a specific signaling pathway 
to cell adhesion molecules in the niche. When leaving the 
niche, stem cell either divides, differentiate or apoptosis.68
 Stem cells niche is used to maintain stem cells' 
identity. It consists of several types of cells. The niche, 
which is composed of extracellular matrix provide the 
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microenvironment to maintain cell as an undifferentiated 
stem cell.69 The quiescence and potency of cell in the niche 
will be maintained to prevent stem cell losing its stemness.68 
If a cells wanted to differentiate, it requires some signaling 
interactions with neighboring cells.67 Niche cell will provide 
an anchorage site, membrane-bound and secreted signal 
molecules to accomplish this function.70 
 Division of stem cell can be either symmetrical 
or asymmetrical. The symmetrical division is known as 
proliferation, it generates two daughter stem cells.66 During 
development periods or after an injury, stem cells will 
expand in numbers.70 The asymmetric division is present 
when stem cell differentiates. The asymmetric cell division 
generates a copy of stem cell itself and the second one with 
limited self-renewal potential. When the cell divided, the 
mitotic spindle is oriented at a right angle to the cells of the 
niche, allowing one remain in contact with the niche while 
the other moves away and differentiates.67 It is to maintain 
the balance of stem cell and differentiated cells.70
 Cell cycles are the mechanism of how cell does a self-
renewal or proliferate.70,71 During proliferation, most stem 
cell control in the S phase (DNA synthase phase) rather than 
G1 phase.71 The length of G1 phase during differentiation of 
human pluripotent stem cells indicates cell-cycle regulation. 
The truncated G1 phase is the character of the pluripotent 
state.72
 Self-renewal is a process of stem cell diving into 
daughter stem cells that have the similar potential for 
the mother cell. Stem cells divide into new cells while 
maintaining the undifferentiated state and also preserve 
they multipotency state.70 The mechanism of the unique 
ability of stem cells to self-renew is controlled by a specific 
mechanism to regulate the progress of their cell cycle.73 This 
mechanism is controlled by stem cell niche which gives the 
extrinsic signal and resulting in the effect of an intrinsic 
genetic pathway of the cells.69 The regulation of circulating 
hormones, cytokines, and/or neural activity also affect the 
signaling in stem cell niche.70
 The self-renewal program involves in the balance 
proto-oncogenes, gate-keeping tumor suppressors, and 
care-taking tumor suppressors that used for promoting and 
limiting self-renewal and maintain genomic integrity. Proto-
oncogenes are used to promote cancer cell proliferation and 
stem cell self-renewal. The suppression of self-renewal is 
controlled by gate-keeping tumor suppressors, resulting in 
stem cell aging. The defects of this mechanism could lead to 
uncontrolled development and cancer.70 Many pathologies 
Figure 4. The stem cell dynamics: the symmetric and 
asymmetric cell division.67 (With permission from Cold Spring 
Harbor Laboratory Press).
such as tissue degeneration, aging, tumorigenesis have been 
associated with dysregulation of stem cell niche. Recent 
studies said that cancer stem cells are dependent on signals 
from their niche.66 
 As a fail-safe mechanism, gate-keeping tumor 
suppressors (p53, p16Ink4a, and p19Arf) prevent 
uncontrolled proliferation by senescence or apoptosis when 
activated by DNA damage, stress, or oncogenic stimuli. 
Care-taking tumor suppressors promote the maintenance of 
stem cell by maintaining the cellular integrity.70 The PI-3 
kinase pathway is essential for the regulation of normal 
stem cell self-renewal and is frequently hyperactivated by 
mutations in cancer.74
 Genomic integrity is important for normal function 
of stem cells. Accumulation genetic lesion could result 
in mutation of large numbers of daughter stem cells.70 
DNA damaged could occur to normal DNA replication, 
exposure to irradiation, chemical mutagen and the product 
of oxidative metabolism, reactive oxygen species (ROS). 
This result of impairing the cellular function and the risk of 
cancer will increase due to the mutation.70 If the damage is 
too extensive, apoptosis or senescence or cell death is one of 
the alternate fates of stem cells.67
 Telomeres, a repetitive DNA sequences located at the 
end of chromosomes serves to protect the chromosome.75 
When DNA replication occurs, 50-150 base pairs of sequence 
at the end of the chromosome are lost in each round resulting 
telomeres become shorter and shorter. This became the limit 
of cell number division because when telomere reached the 
critical length, the cell will go senesces.70 The other function 
of the telomere is used as a protection against exonuclease 
and chromosomes from fusing to each other. Telomeres 
could extend its length because the present of telomerase 
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enzyme by adding new TTAGGG repeats.75 It allows stem 
cells to escape the replication limits and resulting in cancer 
cells because the instability of cells' genetics.70
 Stem cells have the capacity to protect itself from 
endogenous and exogenous mutagen using the repair 
mechanism. DNA damaged can lead to senescence, 
apoptosis, reduced self-renewal potential, or cancer. The 
result of this DNA damage will deplete the stem cell pool 
and reduce tissue regenerative capacity.70,76
Stem cells versus tumor cells
As ESC has its own controversy, adult stem cells are now 
used for regenerative medicine. This due to its ability 
to proliferate and differentiate into a range of progeny. 
However, there is a risk of tumor formation when using 
the stem cells for curing and rehabilitation for regenerative 
medicine. This led the barriers of stem cells’ usage for 
therapy. The ability to proliferate, differentiate, and self-
renewing of stem cells and tumor cells have a common 
mechanism.77
 The connection between stem cells and tumorigenesis 
is still an elusive information. In many cases, normal 
stem cell and cancer cell have similarity in self-renewal 
regulators functions.70 Tumorigenesis is known as a 
transformation of normal cell into a tumor cell which has 
abnormal proliferation.70,77 The mutations that constitutively 
activate oncogenes or inactivate tumor suppressors.70 This 
cell also can differentiate into somatic cell or adult stem cell 
that turns into cancer stem cell (CSC).77 
 MSCs are very popular with the other stem cell to 
be studied and used for cellular therapy.78 It has a great 
potential of regenerative medicine due to its ability and 
immunomodulatory characteristic.79 The modulation of 
MSC local environment for repair and regeneration is 
modulated by the direct cell to cell interaction or secretion of 
immune-related molecules.66 However, in previous studied, 
MSC is found to play roles in facilitating tumorigenesis and 
cancer.66,80,81 
 MSCs are multipotent and also had the ability to 
differentiate from three lineages: chondrocyte, adipocyte, 
and osteocyte.66,82 The characteristic of MSC was determined 
by the expression of CD44, CD73 (ecto-5'-nucleotidase), 
CD90 (Thy-1), CD 105 (endoglin) and HLA-ABC. MSC do 
not express CD34 (hematopoietic progenitor and endothelial 
cell marker), CD45 (pan-leukocyte marker), CD11b or 
CD14 (monocyte and macrophage markers), CD19 or 
CD79 (B cell markers) and HLA-DR (marker of stimulated 
MSCs).66,78,82 In a native niche, MSC became quiescent.66 
However, in recent studies said that the ESC marker such as 
Oct4 SSEA-4, SOX2, Nanog, and alkaline phosphatase was 
expressed MSC derived from bone marrow and adipose.78,83
 The gene and protein expression between 
undifferentiated and differentiated states of MSC are 
reported to be different. Cytokine such as interleukine-6 
(IL-6) is important to maintain MSC state because it 
enhances proliferation and suppresses differentiation in 
the chondrogenic and adipogenic state.66 The molecular 
regulation of MSC differentiation focused on two pathways, 
the Wnt canonical pathway, and the TGF-β superfamily 
pathway.84 Canonical Wnt signaling pathway and 
extracellular matrix molecule alpha 4-laminin also found to 
suppress the differentiation of tri-linage.66
 The immunomodulation function of MSC should 
be viewed as a double-edged weapon.85,86 It poses threats 
to diseases such as cancer. MSC secretes paracrine factor 
such as VEGF and SDF-1, potent chemoattractants to 
endothelial lineage cells, and MIP-1, -2, and MCP-5, major 
chemoattractants to monocytes and macrophages. MSCs 
constitutively secrete a host of inflammatory factors such 
as various interleukins, including IL-6 and GM-CSF.66 It 
was reported that the secretion of TGF-β accelerated the 
differentiation of MSC into cancer-associated fibroblasts 
(CAF) that are recruited to the tumor area in SDF-1α 
dependent manner.87 SDF-1 can trigger CAF cells via 
JAK2/STAT3 and MAPK/ERK signaling pathways 
with the subsequent organization of actin filaments and 
cytoskeleton.88 SDF-1 was reported to recruit endothelial 
progenitor cells (EPCs) which promote the angiogenesis 
and the tumor growth. MSC might provide tumor protection 
against the production of several anti-apoptotic factors such 
as hepatocyte growth factor (HGF), insulin-like growth 
factor (IGF-1), basic fibroblast growth factor (b-FGF) and 
granulocyte/macrophage colony stimulating factor (GM-
CSF). However, MSC could inhibit tumor growth by several 
mechanisms. The secretion of pro-inflammatory cytokines 
that enhance infiltration of macrophages and monocytes 
to the tumor area.86 Such mechanism must be considerate 
during stem cell therapy using MSC.
Summary
As the field of stem cell is rapidly developing lately, many 
types of research have been done to find more information 
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